Rajasekhar Reddy Alavala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rajasekhar Reddy Alavala has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
- Umasankar Kulandaivelu
Medicinal Chemistry Research Division, KL College of Pharmacy, KLEF Deemed to be University, Guntur 522502, India
12 shared publications - Gudhanti Siva Naga Koteswara Rao
Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS, Mumbai, India
8 shared publications Shireesha Boyapati
8 shared publicationsUmasankar Kulandaivelu
K L Deemed to be University, India
8 shared publicationsSiva Prasad Panda
College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Andhra Pradesh, India
5 shared publicationsGsn Koteswara Rao
K L Deemed to be University, India
4 shared publications
Latest Publications
- 17 July 2026
- Published by Wiley in Cell Biochemistry and Function
- Vol. 44 (7) , e70271
Epithelial–Mesenchymal Plasticity in Cancer: Transcriptional Regulation, Biomarker Challenges, and Emerging Therapeutic Opportunities
Epithelial–mesenchymal transition (EMT) is increasingly recognized as a dynamic process of epithelial–mesenchymal plasticity (EMP) rather than a binary switch between epithelial and mesenchymal phenotypes. This plasticity enables tumor cells to acquire invasive, metastatic, stem‐like, and therapy‐resistant characteristics that contribute to cancer progression and poor clinical outcomes. Despite extensive investigation, significant challenges remain in understanding the functional significance of partial EMT states, identifying robust biomarkers that capture EMT heterogeneity, and translating EMT‐targeted interventions into clinical practice. This review critically examines the molecular mechanisms governing EMT, including transcriptional regulators, signaling pathways, epigenetic modifications, and tumor microenvironmental influences. Particular emphasis is placed on hybrid epithelial/mesenchymal states, which have emerged as key drivers of metastatic fitness and therapeutic resistance. We further evaluate established and emerging EMT biomarkers, including E‐cadherin, N‐cadherin, vimentin, circulating tumor cells, and exosome‐derived signatures, highlighting their opportunities and limitations in clinical applications. Finally, we discuss current therapeutic strategies targeting EMT‐associated pathways and explain why many promising preclinical approaches have faced translational barriers. By integrating mechanistic, biomarker, and therapeutic perspectives, this review proposes that understanding and targeting epithelial–mesenchymal plasticity, rather than EMT alone, may provide a more effective framework for precision oncology and metastasis prevention.
- 17 July 2026
- Published by Wiley in Cell Biochemistry and Function
- Vol. 44 (7) , e70271
Epithelial–Mesenchymal Plasticity in Cancer: Transcriptional Regulation, Biomarker Challenges, and Emerging Therapeutic Opportunities
Epithelial–mesenchymal transition (EMT) is increasingly recognized as a dynamic process of epithelial–mesenchymal plasticity (EMP) rather than a binary switch between epithelial and mesenchymal phenotypes. This plasticity enables tumor cells to acquire invasive, metastatic, stem‐like, and therapy‐resistant characteristics that contribute to cancer progression and poor clinical outcomes. Despite extensive investigation, significant challenges remain in understanding the functional significance of partial EMT states, identifying robust biomarkers that capture EMT heterogeneity, and translating EMT‐targeted interventions into clinical practice. This review critically examines the molecular mechanisms governing EMT, including transcriptional regulators, signaling pathways, epigenetic modifications, and tumor microenvironmental influences. Particular emphasis is placed on hybrid epithelial/mesenchymal states, which have emerged as key drivers of metastatic fitness and therapeutic resistance. We further evaluate established and emerging EMT biomarkers, including E‐cadherin, N‐cadherin, vimentin, circulating tumor cells, and exosome‐derived signatures, highlighting their opportunities and limitations in clinical applications. Finally, we discuss current therapeutic strategies targeting EMT‐associated pathways and explain why many promising preclinical approaches have faced translational barriers. By integrating mechanistic, biomarker, and therapeutic perspectives, this review proposes that understanding and targeting epithelial–mesenchymal plasticity, rather than EMT alone, may provide a more effective framework for precision oncology and metastasis prevention.
- Open Access
- 13 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (4) , 3609-3622
Efficient synthesis, dual anti-tubercular and antioxidant activity of triazole-acetophenone derivatives: enhanced efficacy via esterification and quantum mechanical validation of CYP121 binding
Twelve novel triazole-based acetophenone derivatives (3a–3f, 4a–4f) synthesized via catalyst-free cycloaddition integrate a CYP121 inhibiting scaffold with dual anti-tubercular and antioxidant properties.
- 13 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (4) , 3609-3622
Open AccessEfficient synthesis, dual anti-tubercular and antioxidant activity of triazole-acetophenone derivatives: enhanced efficacy via esterification and quantum mechanical validation of CYP121 binding
Twelve novel triazole-based acetophenone derivatives (3a–3f, 4a–4f) synthesized via catalyst-free cycloaddition integrate a CYP121 inhibiting scaffold with dual anti-tubercular and antioxidant properties.
- 1 December 2025
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 25 (28) , 3215-3233
Histone Deacetylase Inhibition in Alzheimer’s Disease: Molecular Mechanisms, Therapeutic Potential, and Future Perspectives
Alzheimer’s disease (AD) remains a formidable challenge in modern medicine, with limited therapeutic options available to combat its progressive cognitive decline. Histone acetylation is a key epigenetic mechanism responsible for gene expression, cell growth, and differentiation. HDAC is a group of enzymes that can reverse the acetylation of cells. These enzymes have been evidenced to be involved in the pathophysiology of AD. Hence, inhibition of this enzyme was postulated to exhibit pronounced benefits in AD concerning memory, learning, and cognition. Pan-HDAC inhibitors inhibited multiple HDAC isoforms but were associated with certain side effects. Hence, class-specific and isoform-specific inhibitors were discovered, revealing great potencies and proving efficacious. This review article comprehensively explores the evolving landscape of research avenues targeting HDAC inhibitors against AD. Beginning with the molecular mechanisms underlying AD pathology, we delve into the intricate roles of HDACs in neurodegeneration and synaptic dysfunction. Subsequently, we scrutinize preclinical studies investigating various HDAC inhibitors, elucidating their promising neuroprotective effects, modulation of epigenetic mechanisms, and potential for disease modification. Furthermore, we highlight the translational challenges and therapeutic opportunities in advancing HDAC inhibitors toward clinical applications for AD. By summarizing current research findings, this review aims to provide valuable insights into the burgeoning field of HDAC inhibition as a promising therapeutic strategy for combating AD, paving the way for future research directions and drug development endeavors.
- 1 December 2025
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 25 (28) , 3215-3233
Histone Deacetylase Inhibition in Alzheimer’s Disease: Molecular Mechanisms, Therapeutic Potential, and Future Perspectives
Alzheimer’s disease (AD) remains a formidable challenge in modern medicine, with limited therapeutic options available to combat its progressive cognitive decline. Histone acetylation is a key epigenetic mechanism responsible for gene expression, cell growth, and differentiation. HDAC is a group of enzymes that can reverse the acetylation of cells. These enzymes have been evidenced to be involved in the pathophysiology of AD. Hence, inhibition of this enzyme was postulated to exhibit pronounced benefits in AD concerning memory, learning, and cognition. Pan-HDAC inhibitors inhibited multiple HDAC isoforms but were associated with certain side effects. Hence, class-specific and isoform-specific inhibitors were discovered, revealing great potencies and proving efficacious. This review article comprehensively explores the evolving landscape of research avenues targeting HDAC inhibitors against AD. Beginning with the molecular mechanisms underlying AD pathology, we delve into the intricate roles of HDACs in neurodegeneration and synaptic dysfunction. Subsequently, we scrutinize preclinical studies investigating various HDAC inhibitors, elucidating their promising neuroprotective effects, modulation of epigenetic mechanisms, and potential for disease modification. Furthermore, we highlight the translational challenges and therapeutic opportunities in advancing HDAC inhibitors toward clinical applications for AD. By summarizing current research findings, this review aims to provide valuable insights into the burgeoning field of HDAC inhibition as a promising therapeutic strategy for combating AD, paving the way for future research directions and drug development endeavors.
- Open Access
- 29 August 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (38) , 31752-31762
Benzothiazole–thiazole hybrids as broad-spectrum antimicrobial agents: synthesis, SAR analysis, and molecular docking against bacterial and fungal targets
The persistent threat of pathogenic microorganisms demands the development of innovative scaffolds with dual antibacterial and antifungal activities. Herein, we report the synthesis and characterization of a novel series of benzothiazole–thiazole hybrids (4a–4f) via a three-step route, confirmed by NMR and MS analyses. The compounds were screened against Gram-positive, Gram-negative, mycobacterial, and fungal strains using disk diffusion and REMA assays. Compounds 4b, 4c, 4d, and 4f showed strong inhibition zones and low MIC values (3.90–15.63 μg mL−1), with 4b emerging as the most potent. Structure–activity relationship (SAR) analysis revealed that electron-withdrawing groups such as nitro and halogens enhanced antimicrobial activity. Molecular docking studies against Staphylococcus aureus and Mycobacterium tuberculosis DNA gyrase and fungal cytochrome P450 14α-demethylase supported the in vitro findings, with key interactions including hydrogen bonding, π–π stacking, and hydrophobic contacts. These results underscore the potential of benzothiazole–thiazole hybrids as multi-target antimicrobial agents and promising candidates for further development.
- 29 August 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (38) , 31752-31762
Open AccessBenzothiazole–thiazole hybrids as broad-spectrum antimicrobial agents: synthesis, SAR analysis, and molecular docking against bacterial and fungal targets
The persistent threat of pathogenic microorganisms demands the development of innovative scaffolds with dual antibacterial and antifungal activities. Herein, we report the synthesis and characterization of a novel series of benzothiazole–thiazole hybrids (4a–4f) via a three-step route, confirmed by NMR and MS analyses. The compounds were screened against Gram-positive, Gram-negative, mycobacterial, and fungal strains using disk diffusion and REMA assays. Compounds 4b, 4c, 4d, and 4f showed strong inhibition zones and low MIC values (3.90–15.63 μg mL−1), with 4b emerging as the most potent. Structure–activity relationship (SAR) analysis revealed that electron-withdrawing groups such as nitro and halogens enhanced antimicrobial activity. Molecular docking studies against Staphylococcus aureus and Mycobacterium tuberculosis DNA gyrase and fungal cytochrome P450 14α-demethylase supported the in vitro findings, with key interactions including hydrogen bonding, π–π stacking, and hydrophobic contacts. These results underscore the potential of benzothiazole–thiazole hybrids as multi-target antimicrobial agents and promising candidates for further development.
- 1 July 2025
- Published by Springer Nature in Inflammopharmacology
- p. 1-17
Rethinking arthritis: exploring its types and emerging management strategies
Arthritis is a complex group of disorders characterized by inflammation of the joints and poses a significant burden on global health. The most prevalent types of arthritis are osteoarthritis, rheumatoid arthritis, psoriatic arthritis, gouty arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. These types affect millions of individuals worldwide, leading to impaired mobility and reduced quality of life. This review delves into the pathophysiology, clinical manifestations, and progression of these primary arthritis types while shedding light on over 39 lesser-prevalent variants. Traditional management strategies, including pharmacological and non-pharmacological interventions, have shown limited success in halting disease progression and mitigating long-term damage. Consequently, arthritis research has shifted towards emerging therapeutic strategies such as nanotechnology-based drug delivery systems, diet modifications, stem cell, and gene therapy approaches. Telemedicine and artificial intelligence are revolutionizing arthritis care by enabling personalized treatment regimes, improving diagnostic accuracy, and optimizing patient outcomes. This paper underscores the need for a multi-faceted approach to arthritis management, emphasizing micromanagement at the cellular and molecular levels to address the heterogeneity of the disease. Understanding the nuances of different arthritis types and leveraging innovative therapeutic technologies will be paramount in improving patient prognosis and minimizing the societal burden of this debilitating condition.
- 1 July 2025
- Published by Springer Nature in Inflammopharmacology
- p. 1-17
Rethinking arthritis: exploring its types and emerging management strategies
Arthritis is a complex group of disorders characterized by inflammation of the joints and poses a significant burden on global health. The most prevalent types of arthritis are osteoarthritis, rheumatoid arthritis, psoriatic arthritis, gouty arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. These types affect millions of individuals worldwide, leading to impaired mobility and reduced quality of life. This review delves into the pathophysiology, clinical manifestations, and progression of these primary arthritis types while shedding light on over 39 lesser-prevalent variants. Traditional management strategies, including pharmacological and non-pharmacological interventions, have shown limited success in halting disease progression and mitigating long-term damage. Consequently, arthritis research has shifted towards emerging therapeutic strategies such as nanotechnology-based drug delivery systems, diet modifications, stem cell, and gene therapy approaches. Telemedicine and artificial intelligence are revolutionizing arthritis care by enabling personalized treatment regimes, improving diagnostic accuracy, and optimizing patient outcomes. This paper underscores the need for a multi-faceted approach to arthritis management, emphasizing micromanagement at the cellular and molecular levels to address the heterogeneity of the disease. Understanding the nuances of different arthritis types and leveraging innovative therapeutic technologies will be paramount in improving patient prognosis and minimizing the societal burden of this debilitating condition.
- Open Access
- 29 April 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (5) , 582
Correction: Rasool et al. Non-Invasive Delivery of Nano-Emulsified Sesame Oil-Extract of Turmeric Attenuates Lung Inflammation. Pharmaceutics 2020, 12, 1206
In the original publication, there was a mistake in Figure 8 as published
- 29 April 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (5) , 582
Open AccessCorrection: Rasool et al. Non-Invasive Delivery of Nano-Emulsified Sesame Oil-Extract of Turmeric Attenuates Lung Inflammation. Pharmaceutics 2020, 12, 1206
In the original publication, there was a mistake in Figure 8 as published
- 22 April 2025
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 118, 108478
Identification of novel ligands against GSK-3β: Molecular docking, ADMET filtering, MD simulations, MM-GBSA studies, and DFT analysis
- 22 April 2025
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 118, 108478
Identification of novel ligands against GSK-3β: Molecular docking, ADMET filtering, MD simulations, MM-GBSA studies, and DFT analysis
- 4 February 2025
- Published by Wiley in Chemistry & Biodiversity
- Vol. 22 (6) , e202402631
Acetohydroxyacid Synthase (AHAS) Inhibitors as Antitubercular Agents: Insights From Molecular Docking and Dynamics Simulations
Acetohydroxyacid synthase (AHAS) is a vital enzyme in Mycobacterium tuberculosis , the pathogen causing tuberculosis (TB), involved in branched‐chain amino acid synthesis. Targeting AHAS for drug design against TB offers a promising strategy due to its essentiality in bacterial growth. In current investigation, we have designed 160 novel compounds by leveraging key scaffolds identified through structure‐based drug design (SBDD) methodologies. Subsequently, these compounds underwent molecular docking analysis to elucidate their potential interactions with the AHAS protein. The Top 4 compounds (with docking score above −8.2 kcal/mol) resulting from the docking studies were subjected to rigorous molecular dynamics simulations, spanning a runtime of 100 ns, to assess their stability across various parameters including root mean square deviation (RMSD), root mean square fluctuation (RMSF), secondary structure elements (SSEs), radius of gyration (rGyr), solvent accessible surface area (SASA), and MM‐GBSA free energy values. Remarkably, compounds KG 98 and KG 131 exhibited superior stability profiles across all analyzed parameters. From the detailed interactions analysis, it was found that the nitrogen containing heterocyclic rings (1,3,5‐triazine/imidazole) are essential to have the potential binding interactions with the AHAS enzyme. Some of the interactions were persisted for more than 75% of the simulated time, which shows the strength of the interactions. The findings suggest these lead molecules as promising candidates for AHAS inhibition, a potential avenue for TB treatment and management.
- 4 February 2025
- Published by Wiley in Chemistry & Biodiversity
- Vol. 22 (6) , e202402631
Acetohydroxyacid Synthase (AHAS) Inhibitors as Antitubercular Agents: Insights From Molecular Docking and Dynamics Simulations
Acetohydroxyacid synthase (AHAS) is a vital enzyme in Mycobacterium tuberculosis , the pathogen causing tuberculosis (TB), involved in branched‐chain amino acid synthesis. Targeting AHAS for drug design against TB offers a promising strategy due to its essentiality in bacterial growth. In current investigation, we have designed 160 novel compounds by leveraging key scaffolds identified through structure‐based drug design (SBDD) methodologies. Subsequently, these compounds underwent molecular docking analysis to elucidate their potential interactions with the AHAS protein. The Top 4 compounds (with docking score above −8.2 kcal/mol) resulting from the docking studies were subjected to rigorous molecular dynamics simulations, spanning a runtime of 100 ns, to assess their stability across various parameters including root mean square deviation (RMSD), root mean square fluctuation (RMSF), secondary structure elements (SSEs), radius of gyration (rGyr), solvent accessible surface area (SASA), and MM‐GBSA free energy values. Remarkably, compounds KG 98 and KG 131 exhibited superior stability profiles across all analyzed parameters. From the detailed interactions analysis, it was found that the nitrogen containing heterocyclic rings (1,3,5‐triazine/imidazole) are essential to have the potential binding interactions with the AHAS enzyme. Some of the interactions were persisted for more than 75% of the simulated time, which shows the strength of the interactions. The findings suggest these lead molecules as promising candidates for AHAS inhibition, a potential avenue for TB treatment and management.